- Home
- ETON vs TSSI Comparison
ETON vs TSSI Comparison
Compare ETON & TSSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- TSSI
- Stock Information
- Founded
- ETON 2017
- TSSI 2004
- Country
- ETON United States
- TSSI United States
- Employees
- ETON N/A
- TSSI N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- TSSI Professional Services
- Sector
- ETON Health Care
- TSSI Consumer Discretionary
- Exchange
- ETON Nasdaq
- TSSI Nasdaq
- Market Cap
- ETON 498.8M
- TSSI 572.8M
- IPO Year
- ETON 2018
- TSSI N/A
- Fundamental
- Price
- ETON $16.95
- TSSI $15.27
- Analyst Decision
- ETON Strong Buy
- TSSI
- Analyst Count
- ETON 3
- TSSI 0
- Target Price
- ETON $29.67
- TSSI N/A
- AVG Volume (30 Days)
- ETON 278.7K
- TSSI 1.5M
- Earning Date
- ETON 11-06-2025
- TSSI 11-13-2025
- Dividend Yield
- ETON N/A
- TSSI N/A
- EPS Growth
- ETON N/A
- TSSI 311.74
- EPS
- ETON N/A
- TSSI 0.34
- Revenue
- ETON $70,316,000.00
- TSSI $263,021,000.00
- Revenue This Year
- ETON $105.25
- TSSI N/A
- Revenue Next Year
- ETON $40.84
- TSSI N/A
- P/E Ratio
- ETON N/A
- TSSI $47.10
- Revenue Growth
- ETON 102.77
- TSSI 328.79
- 52 Week Low
- ETON $8.43
- TSSI $5.63
- 52 Week High
- ETON $23.00
- TSSI $31.94
- Technical
- Relative Strength Index (RSI)
- ETON 38.74
- TSSI 39.01
- Support Level
- ETON $16.34
- TSSI $15.51
- Resistance Level
- ETON $18.15
- TSSI $16.80
- Average True Range (ATR)
- ETON 1.08
- TSSI 1.35
- MACD
- ETON -0.14
- TSSI -0.30
- Stochastic Oscillator
- ETON 14.34
- TSSI 4.39
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About TSSI TSS Inc.
TSS Inc provides various services for planning, design, development, and maintenance of mission-critical facilities and information infrastructure, as well as integration services. Its services consist of technology consulting, design and engineering, project management, systems integration, systems installation, facilities management, and IT procurement services. The activities are organized into two segments: Procurement, Systems Integration, and Facilities Management. It generates the majority of its revenue from the Procurement segment.